Lessons from maraviroc clinical trials

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Maraviroc is the first commercially available HIV chemokine receptor antagonist targeting HIV that utilizes the CCR5 chemokine receptor (R5 tropic). The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) trials were two randomized, placebo-controlled studies designed to demonstrate the activity of maraviroc in triple-class-experienced HIV individuals, with a primary end point of viral load suppression at 48 weeks. Maraviroc outperformed the placebo plus optimized background (OBT) arm, and exhibited a favorable safety profile with low discontinuation rates, which equaled those of the placebo plus OBT group. The results of these trials led to maraviroc receiving regulatory approval for the treatment of HIV.

Original languageEnglish (US)
Pages (from-to)649-651
Number of pages3
JournalExpert Review of Anti-Infective Therapy
Volume9
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Clinical Trials
Chemokine Receptors
Placebos
HIV
HIV Receptors
CCR5 Receptors
Viral Load
Therapeutics
maraviroc
Safety

Keywords

  • CCR5 antagonist
  • maraviroc
  • R5-tropic HIV
  • randomized controlled trial
  • triple-class failure

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology

Cite this

Lessons from maraviroc clinical trials. / Troia-Cancio, Paolo; Asmuth, David.

In: Expert Review of Anti-Infective Therapy, Vol. 9, No. 6, 06.2011, p. 649-651.

Research output: Contribution to journalArticle

@article{c18bc9551a144dff9f22c3672681c6d6,
title = "Lessons from maraviroc clinical trials",
abstract = "Maraviroc is the first commercially available HIV chemokine receptor antagonist targeting HIV that utilizes the CCR5 chemokine receptor (R5 tropic). The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) trials were two randomized, placebo-controlled studies designed to demonstrate the activity of maraviroc in triple-class-experienced HIV individuals, with a primary end point of viral load suppression at 48 weeks. Maraviroc outperformed the placebo plus optimized background (OBT) arm, and exhibited a favorable safety profile with low discontinuation rates, which equaled those of the placebo plus OBT group. The results of these trials led to maraviroc receiving regulatory approval for the treatment of HIV.",
keywords = "CCR5 antagonist, maraviroc, R5-tropic HIV, randomized controlled trial, triple-class failure",
author = "Paolo Troia-Cancio and David Asmuth",
year = "2011",
month = "6",
doi = "10.1586/eri.11.52",
language = "English (US)",
volume = "9",
pages = "649--651",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Lessons from maraviroc clinical trials

AU - Troia-Cancio, Paolo

AU - Asmuth, David

PY - 2011/6

Y1 - 2011/6

N2 - Maraviroc is the first commercially available HIV chemokine receptor antagonist targeting HIV that utilizes the CCR5 chemokine receptor (R5 tropic). The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) trials were two randomized, placebo-controlled studies designed to demonstrate the activity of maraviroc in triple-class-experienced HIV individuals, with a primary end point of viral load suppression at 48 weeks. Maraviroc outperformed the placebo plus optimized background (OBT) arm, and exhibited a favorable safety profile with low discontinuation rates, which equaled those of the placebo plus OBT group. The results of these trials led to maraviroc receiving regulatory approval for the treatment of HIV.

AB - Maraviroc is the first commercially available HIV chemokine receptor antagonist targeting HIV that utilizes the CCR5 chemokine receptor (R5 tropic). The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) trials were two randomized, placebo-controlled studies designed to demonstrate the activity of maraviroc in triple-class-experienced HIV individuals, with a primary end point of viral load suppression at 48 weeks. Maraviroc outperformed the placebo plus optimized background (OBT) arm, and exhibited a favorable safety profile with low discontinuation rates, which equaled those of the placebo plus OBT group. The results of these trials led to maraviroc receiving regulatory approval for the treatment of HIV.

KW - CCR5 antagonist

KW - maraviroc

KW - R5-tropic HIV

KW - randomized controlled trial

KW - triple-class failure

UR - http://www.scopus.com/inward/record.url?scp=79959756297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959756297&partnerID=8YFLogxK

U2 - 10.1586/eri.11.52

DO - 10.1586/eri.11.52

M3 - Article

C2 - 21692669

AN - SCOPUS:79959756297

VL - 9

SP - 649

EP - 651

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 6

ER -